However, a recent study using VE-821 (an analog of VX-970) and a Chk1 inhibitor, in a small number of ovarian cancer lines, concluded that the sensitization profiles of these two compounds can be different[33]. This evidence concerns the gene CHEK1 and ovarian cancer.